XYREM® Manufacturing Services and Supply Agreement Between Patheon Pharmaceuticals Inc. and Jazz Pharmaceuticals, Inc.Manufacturing Services and Supply Agreement • May 31st, 2007 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS MANUFACTURING SERVICES AND SUPPLY AGREEMENT (the "Agreement") made as of the 13th day of March, 2007, and with an Effective Date and a Manufacturing Commencement Date as set forth below.
LICENSE AGREEMENT by and between SOLVAY PHARMACEUTICALS, INC. and JAZZ PHARMACEUTICALS, INC. relating to LUVOX®-IR (fluvoxamine) and LUVOX®-ER (fluvoxamine extended release) Dated January 31, 2007License Agreement • May 31st, 2007 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”) is made and entered into as of the 31st day of January, 2007 (“Effective Date”), by and between SOLVAY PHARMACEUTICALS, INC., a Georgia corporation having its principal office at 901 Sawyer Road, Marietta, Georgia 30062 (“Solvay”) and JAZZ PHARMACEUTICALS, INC., a Delaware corporation, having its principal offices at 3180 Porter Drive, Palo Alto, California 94304 (“Jazz Pharmaceuticals”). Solvay and Jazz Pharmaceuticals are referred to herein on occasion separately as a “Party” or together as the “Parties”.
7 November 2006 ELAN CORPORATION, PLC. AND SOLVAY PHARMACEUTICALS INC. AMENDMENT AGREEMENT NO. 3 TO THE LICENCE AGREEMENT OF 22 DECEMBER 1997Licensing Agreement • May 31st, 2007 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations • Georgia
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • May 31st, 2007 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations • New York
This ASSET PURCHASE AGREEMENT (the “Agreement”) is made as of this 4th day of October, 2004 by and between Glaxo Group Limited, a company incorporated under the laws of England and Wales with offices at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, UK (“GGL”), SmithKline Beecham Corporation, doing business as GlaxoSmithKline, a company incorporated under the laws of the Commonwealth of Pennsylvania with offices at One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19101 U.S.A. (“SB”) (GGL and SB are collectively referred to in this Agreement as “GSK”), and Jazz Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware with offices at 3180 Porter Drive, Palo Alto, California 94304, U.S. (“Jazz Pharmaceuticals”). GSK and Jazz Pharmaceuticals are referred to herein on occasion separately as a “Party” or together as the “Parties”.
This Agreement is made the 22nd day of December 1997License Agreement • May 31st, 2007 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations • Georgia
• ELAN is beneficially entitled to the use of various patents, including the ELAN PATENT RIGHTS, which have been granted or are pending under the International Convention in relation to the development and production of drug specific dosage forms for pharmaceutical products and process, and
AMENDED AND RESTATED XYREM LICENSE AND DISTRIBUTION AGREEMENTLicense and Distribution Agreement • May 31st, 2007 • Jazz Pharmaceuticals Inc • Pharmaceutical preparations • New York
This AMENDED AND RESTATED LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into as of June 30, 2006 (“Execution Date”), by and between Jazz Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 3180 Porter Drive, Palo Alto, California 94304, USA (together with its Affiliates, “Jazz Pharmaceuticals”), and UCB Pharma Limited, a company organized under the laws of England having its principal place of business at 208 Bath Road, Slough, Berkshire, SL1 3WE (together with its Affiliates, “UCB”).
